Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder

Yu Ko, Daniel C. Malone, Edward P. Armstrong

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Study Objective. To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB). Methods. A decision-analysis model was developed and included clinical outcomes (i.e., therapy continued or discontinued, treatment success or failure, OAB-induced comorbidities) and costs for drugs and treatment of OAB-induced comorbidities (i.e., urinary tract infections, fractures, depression, and skin infections). Treatment success was defined as complete continence. A systematic MEDLINE literature search from January 1990-January 2006 identified English-language articles concerning the eight antimuscarinic drugs: darifenacin, solifenacin, trospium, immediate-release oxybutynin, extended-release oxybutynin, transdermal oxybutynin, immediate-release tolterodine, and extended-release tolterodine. Probabilities and cost data for these drugs were retrieved from the literature, and drug costs were based on 2005 average wholesale prices. The analysis was constructed from a payer's perspective. The time frame for the model was 3 months. Results. Expected costs for each patient with OAB ranged from $3373 when treated with solifenacin to $3769 when treated with immediate-release oxybutynin. The average cost/patient with continued and successful treatment was lowest for solifenacin ($6863). Solifenacin dominated all other antimuscarinic agents because they were associated with high costs and low effectiveness. Success rates were the key parameters driving the sensitivity analysis. Conclusion. Among various antimuscarinic agents, solifenacin 5 mg had the lowest costs and highest effectiveness in the treatment of OAB.

Original languageEnglish
Pages (from-to)1694-1702
Number of pages9
JournalPharmacotherapy
Volume26
Issue number12 I
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Fingerprint

Overactive Urinary Bladder
Pharmaceutical Economics
Muscarinic Antagonists
Drug Costs
Cost-Benefit Analysis
Comorbidity
Therapeutics
Costs and Cost Analysis
Decision Support Techniques
Urinary Tract Infections
MEDLINE
Health Care Costs
Language
Solifenacin Succinate
Depression
Skin
oxybutynin
Infection
Pharmaceutical Preparations

Keywords

  • Antimus-carinic agents
  • Cost-effectiveness analysis
  • Darifenacin
  • Decision analytic model
  • Decision-analysis model
  • OAB
  • Overactive bladder
  • Oxybutynin
  • Solifenacin
  • Tolterodine
  • Trospium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. / Ko, Yu; Malone, Daniel C.; Armstrong, Edward P.

In: Pharmacotherapy, Vol. 26, No. 12 I, 12.2006, p. 1694-1702.

Research output: Contribution to journalArticle

Ko, Yu ; Malone, Daniel C. ; Armstrong, Edward P. / Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. In: Pharmacotherapy. 2006 ; Vol. 26, No. 12 I. pp. 1694-1702.
@article{d1519ba4483747e092bdf497e2ed3a0b,
title = "Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder",
abstract = "Study Objective. To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB). Methods. A decision-analysis model was developed and included clinical outcomes (i.e., therapy continued or discontinued, treatment success or failure, OAB-induced comorbidities) and costs for drugs and treatment of OAB-induced comorbidities (i.e., urinary tract infections, fractures, depression, and skin infections). Treatment success was defined as complete continence. A systematic MEDLINE literature search from January 1990-January 2006 identified English-language articles concerning the eight antimuscarinic drugs: darifenacin, solifenacin, trospium, immediate-release oxybutynin, extended-release oxybutynin, transdermal oxybutynin, immediate-release tolterodine, and extended-release tolterodine. Probabilities and cost data for these drugs were retrieved from the literature, and drug costs were based on 2005 average wholesale prices. The analysis was constructed from a payer's perspective. The time frame for the model was 3 months. Results. Expected costs for each patient with OAB ranged from $3373 when treated with solifenacin to $3769 when treated with immediate-release oxybutynin. The average cost/patient with continued and successful treatment was lowest for solifenacin ($6863). Solifenacin dominated all other antimuscarinic agents because they were associated with high costs and low effectiveness. Success rates were the key parameters driving the sensitivity analysis. Conclusion. Among various antimuscarinic agents, solifenacin 5 mg had the lowest costs and highest effectiveness in the treatment of OAB.",
keywords = "Antimus-carinic agents, Cost-effectiveness analysis, Darifenacin, Decision analytic model, Decision-analysis model, OAB, Overactive bladder, Oxybutynin, Solifenacin, Tolterodine, Trospium",
author = "Yu Ko and Malone, {Daniel C.} and Armstrong, {Edward P.}",
year = "2006",
month = "12",
doi = "10.1592/phco.26.12.1694",
language = "English",
volume = "26",
pages = "1694--1702",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12 I",

}

TY - JOUR

T1 - Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder

AU - Ko, Yu

AU - Malone, Daniel C.

AU - Armstrong, Edward P.

PY - 2006/12

Y1 - 2006/12

N2 - Study Objective. To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB). Methods. A decision-analysis model was developed and included clinical outcomes (i.e., therapy continued or discontinued, treatment success or failure, OAB-induced comorbidities) and costs for drugs and treatment of OAB-induced comorbidities (i.e., urinary tract infections, fractures, depression, and skin infections). Treatment success was defined as complete continence. A systematic MEDLINE literature search from January 1990-January 2006 identified English-language articles concerning the eight antimuscarinic drugs: darifenacin, solifenacin, trospium, immediate-release oxybutynin, extended-release oxybutynin, transdermal oxybutynin, immediate-release tolterodine, and extended-release tolterodine. Probabilities and cost data for these drugs were retrieved from the literature, and drug costs were based on 2005 average wholesale prices. The analysis was constructed from a payer's perspective. The time frame for the model was 3 months. Results. Expected costs for each patient with OAB ranged from $3373 when treated with solifenacin to $3769 when treated with immediate-release oxybutynin. The average cost/patient with continued and successful treatment was lowest for solifenacin ($6863). Solifenacin dominated all other antimuscarinic agents because they were associated with high costs and low effectiveness. Success rates were the key parameters driving the sensitivity analysis. Conclusion. Among various antimuscarinic agents, solifenacin 5 mg had the lowest costs and highest effectiveness in the treatment of OAB.

AB - Study Objective. To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB). Methods. A decision-analysis model was developed and included clinical outcomes (i.e., therapy continued or discontinued, treatment success or failure, OAB-induced comorbidities) and costs for drugs and treatment of OAB-induced comorbidities (i.e., urinary tract infections, fractures, depression, and skin infections). Treatment success was defined as complete continence. A systematic MEDLINE literature search from January 1990-January 2006 identified English-language articles concerning the eight antimuscarinic drugs: darifenacin, solifenacin, trospium, immediate-release oxybutynin, extended-release oxybutynin, transdermal oxybutynin, immediate-release tolterodine, and extended-release tolterodine. Probabilities and cost data for these drugs were retrieved from the literature, and drug costs were based on 2005 average wholesale prices. The analysis was constructed from a payer's perspective. The time frame for the model was 3 months. Results. Expected costs for each patient with OAB ranged from $3373 when treated with solifenacin to $3769 when treated with immediate-release oxybutynin. The average cost/patient with continued and successful treatment was lowest for solifenacin ($6863). Solifenacin dominated all other antimuscarinic agents because they were associated with high costs and low effectiveness. Success rates were the key parameters driving the sensitivity analysis. Conclusion. Among various antimuscarinic agents, solifenacin 5 mg had the lowest costs and highest effectiveness in the treatment of OAB.

KW - Antimus-carinic agents

KW - Cost-effectiveness analysis

KW - Darifenacin

KW - Decision analytic model

KW - Decision-analysis model

KW - OAB

KW - Overactive bladder

KW - Oxybutynin

KW - Solifenacin

KW - Tolterodine

KW - Trospium

UR - http://www.scopus.com/inward/record.url?scp=33845364076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845364076&partnerID=8YFLogxK

U2 - 10.1592/phco.26.12.1694

DO - 10.1592/phco.26.12.1694

M3 - Article

C2 - 17125433

AN - SCOPUS:33845364076

VL - 26

SP - 1694

EP - 1702

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12 I

ER -